Source: International Congress 2018 – New developments in the treatment of asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Carlsson (Mölndal, Sweden), M. Braddock (Cambridge, United Kingdom), Y. Li (Gaithersburg, United States of America), J. Wang (Gaithersburg, United States of America), W. Xu (Gaithersburg, United States of America), G. Colice (Gaithersburg, United States of America). No clinically relevant hypersensitivity reactions in clinical trials with tralokinumab in asthma. 1034

Member's Comments

No comment yet.

Related content which might interest you: A randomized double-blind study of specific immunotherapy (SIT) in patients with seasonal allergic rhinitis: effects on clinical and inflammatory markers Source: Eur Respir J 2001; 18: Suppl. 33, 482s Year: 2001 A proof-of-concept randomized-controlled trial of omalizumab in patients with severe difficult to control nonatopic asthma Source: Annual Congress 2012 - Clinical diagnosis and treatment of adult asthma Year: 2012 Using placebo-controlled trials to define predictors of future exacerbations in severe asthma patients Source: Eur Respir J, 58 (6) 2101702; 10.1183/13993003.01702-2021 Year: 2021 A randomized controlled study of omalizumab in children with moderate-to-severe persistent allergic asthma Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma Year: 2008 COPD treatment from pathophysiology to clinical trials Source: ERS Live 2007 Year: 2007 Asthma and allergic rhinitis - clinical presentation of effects different types of drugs Source: Eur Respir J 2005; 26: Suppl. 49, 506s Year: 2005 Endotypes of severe allergic asthma patients who clinically benefit from Anti-IgE therapy Source: International Congress 2018 – Studying novel biomarkers in asthma and COPD Year: 2018 Patients’ perception of allergic asthma and their compliance to omalizumab in an Italian clinical setting Source: International Congress 2017 – Asthma management Year: 2017 Heterogeneity of treatment response in bronchiectasis clinical trials Source: Virtual Congress 2020 – New investigations of bronchiectasis and non-tuberculous mycobacteria Year: 2020 Variability and lack of predictive ability of asthma end-points in clinical trials Source: Eur Respir J 2002; 20: 1102-1109 Year: 2002 Measuring bronchodilation in COPD clinical trials Source: Eur Respir J 2004; 24: Suppl. 48, 122s Year: 2004 Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Real-life effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma at a single UK hospital Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Persistency of treatment response to omalizumab in patients with severe allergic (IgE-mediated) asthma Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 A randomised clinical trial of feedback on inhaler adherence and technique in patients with severe uncontrolled asthma Source: Eur Respir J, 51 (1) 1701126; 10.1183/13993003.01126-2017 Year: 2018 Omalizumab reduces asthma exacerbations and oral corticosteroid use in patients with severe allergic asthma: a systematic review of observational studies Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019 Dupilumab improves patient-reported outcomes in uncontrolled persistent asthma patients with ongoing allergic rhinitis Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Clinical effectiveness of MDI-HFA-Modulite budesonide in the treatment of asthma – meta-analysis of randomised controlled trials Source: Eur Respir J 2006; 28: Suppl. 50, 315s Year: 2006 Anti-IgE: lessons from clinical trials in patients with severe allergic asthma symptomatic despite optimised therapy Source: Eur Respir Rev 2007; 16: 73-77 Year: 2007